Literature DB >> 33574301

Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer.

Christer Larsson1, Anna Ehinger2, Sofia Winslow3, Karin Leandersson4, Marie Klintman2, Ludvig Dahl2, Johan Vallon-Christersson2, Jari Häkkinen2, Cecilia Hegardt2, Jonas Manjer5, Lao Saal2, Lisa Rydén6, Martin Malmberg2, Åke Borg2, Niklas Loman2.   

Abstract

The extent and composition of the immune response in a breast cancer is one important prognostic factor for the disease. The aim of the current work was to refine the analysis of the humoral component of an immune response in breast tumors by quantifying mRNA expression of different immunoglobulin classes and study their association with prognosis. We used RNA-Seq data from two local population-based breast cancer cohorts to determine the expression of IGJ and immunoglobulin heavy (IGH) chain-encoding RNAs. The association with prognosis was investigated and public data sets were used to corroborate the findings. Except for IGHE and IGHD, mRNAs encoding heavy chains were generally detected at substantial levels and correlated with other immune-related genes. High IGHG1 mRNA was associated with factors related to poor prognosis such as estrogen receptor negativity, HER2 amplification, and high grade, whereas high IGHA2 mRNA levels were primarily associated with lower age at diagnosis. High IGHA2 and IGJ mRNA levels were associated with a more favorable prognosis both in univariable and multivariable Cox models. When adjusting for other prognostic factors, high IGHG1 mRNA levels were positively associated with improved prognosis. To our knowledge, these results are the first to demonstrate that expression of individual Ig class types has prognostic implications in breast cancer.

Year:  2020        PMID: 33574301     DOI: 10.1038/s41523-020-0170-2

Source DB:  PubMed          Journal:  NPJ Breast Cancer        ISSN: 2374-4677


  49 in total

1.  Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Authors:  Makiko Ono; Hitoshi Tsuda; Chikako Shimizu; Sohei Yamamoto; Tatsuhiro Shibata; Harukaze Yamamoto; Taizo Hirata; Kan Yonemori; Masashi Ando; Kenji Tamura; Noriyuki Katsumata; Takayuki Kinoshita; Yuichi Takiguchi; Hideki Tanzawa; Yasuhiro Fujiwara
Journal:  Breast Cancer Res Treat       Date:  2011-05-12       Impact factor: 4.872

2.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

Authors:  Sahar M A Mahmoud; Emma Claire Paish; Desmond G Powe; R Douglas Macmillan; Matthew J Grainge; Andrew H S Lee; Ian O Ellis; Andrew R Green
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

3.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

4.  PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Hallie Wimberly; Jason R Brown; Kurt Schalper; Herbert Haack; Matthew R Silver; Christian Nixon; Veerle Bossuyt; Lajos Pusztai; Donald R Lannin; David L Rimm
Journal:  Cancer Immunol Res       Date:  2014-12-19       Impact factor: 11.151

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

6.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

7.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

Authors:  Carsten Denkert; Sibylle Loibl; Aurelia Noske; Marc Roller; Berit Maria Müller; Martina Komor; Jan Budczies; Silvia Darb-Esfahani; Ralf Kronenwett; Claus Hanusch; Christian von Törne; Wilko Weichert; Knut Engels; Christine Solbach; Iris Schrader; Manfred Dietel; Gunter von Minckwitz
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

8.  The prognostic significance of B lymphocytes in invasive carcinoma of the breast.

Authors:  S M A Mahmoud; A H S Lee; E C Paish; R D Macmillan; I O Ellis; A R Green
Journal:  Breast Cancer Res Treat       Date:  2011-06-14       Impact factor: 4.872

9.  CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.

Authors:  Shuzhen Liu; Jonathan Lachapelle; Samuel Leung; Dongxia Gao; William D Foulkes; Torsten O Nielsen
Journal:  Breast Cancer Res       Date:  2012-03-15       Impact factor: 6.466

10.  Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Authors:  Serena Nik-Zainal; Helen Davies; Johan Staaf; Manasa Ramakrishna; Dominik Glodzik; Xueqing Zou; Inigo Martincorena; Ludmil B Alexandrov; Sancha Martin; David C Wedge; Peter Van Loo; Young Seok Ju; Marcel Smid; Arie B Brinkman; Sandro Morganella; Miriam R Aure; Ole Christian Lingjærde; Anita Langerød; Markus Ringnér; Sung-Min Ahn; Sandrine Boyault; Jane E Brock; Annegien Broeks; Adam Butler; Christine Desmedt; Luc Dirix; Serge Dronov; Aquila Fatima; John A Foekens; Moritz Gerstung; Gerrit K J Hooijer; Se Jin Jang; David R Jones; Hyung-Yong Kim; Tari A King; Savitri Krishnamurthy; Hee Jin Lee; Jeong-Yeon Lee; Yilong Li; Stuart McLaren; Andrew Menzies; Ville Mustonen; Sarah O'Meara; Iris Pauporté; Xavier Pivot; Colin A Purdie; Keiran Raine; Kamna Ramakrishnan; F Germán Rodríguez-González; Gilles Romieu; Anieta M Sieuwerts; Peter T Simpson; Rebecca Shepherd; Lucy Stebbings; Olafur A Stefansson; Jon Teague; Stefania Tommasi; Isabelle Treilleux; Gert G Van den Eynden; Peter Vermeulen; Anne Vincent-Salomon; Lucy Yates; Carlos Caldas; Laura van't Veer; Andrew Tutt; Stian Knappskog; Benita Kiat Tee Tan; Jos Jonkers; Åke Borg; Naoto T Ueno; Christos Sotiriou; Alain Viari; P Andrew Futreal; Peter J Campbell; Paul N Span; Steven Van Laere; Sunil R Lakhani; Jorunn E Eyfjord; Alastair M Thompson; Ewan Birney; Hendrik G Stunnenberg; Marc J van de Vijver; John W M Martens; Anne-Lise Børresen-Dale; Andrea L Richardson; Gu Kong; Gilles Thomas; Michael R Stratton
Journal:  Nature       Date:  2016-05-02       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.